316 related articles for article (PubMed ID: 26988552)
1. Non-metastatic castrate-resistant prostate cancer: a call for improved guidance on clinical management.
Rozet F; Roumeguère T; Spahn M; Beyersdorff D; Hammerer P
World J Urol; 2016 Nov; 34(11):1505-1513. PubMed ID: 26988552
[TBL] [Abstract][Full Text] [Related]
2. Managing Nonmetastatic Castration-resistant Prostate Cancer.
Mateo J; Fizazi K; Gillessen S; Heidenreich A; Perez-Lopez R; Oyen WJG; Shore N; Smith M; Sweeney C; Tombal B; Tomlins SA; de Bono JS
Eur Urol; 2019 Feb; 75(2):285-293. PubMed ID: 30119985
[TBL] [Abstract][Full Text] [Related]
3. The treatment landscape of nonmetastatic castrate resistant prostate cancer: A contemporary perspective.
Yanada BA; Homewood D; Dias BH; Ogluszko C; Corcoran NM
Urol Oncol; 2024 Jun; 42(6):175.e9-175.e18. PubMed ID: 38555235
[TBL] [Abstract][Full Text] [Related]
4. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract][Full Text] [Related]
5. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors.
Saad F; Bögemann M; Suzuki K; Shore N
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):323-334. PubMed ID: 33558665
[TBL] [Abstract][Full Text] [Related]
6. Management of nonmetastatic castration-resistant prostate cancer.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):366-371. PubMed ID: 30015690
[TBL] [Abstract][Full Text] [Related]
7. The utility of prostate-specific antigen in the management of advanced prostate cancer.
Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP
BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876
[TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
[TBL] [Abstract][Full Text] [Related]
10. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment.
Anantharaman A; Small EJ
Expert Rev Anticancer Ther; 2017 Jul; 17(7):625-633. PubMed ID: 28532278
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
12. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
13. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
14. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhang F; Lu YP
Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
[TBL] [Abstract][Full Text] [Related]
15. Management of castrate-resistant prostate cancer in older men.
Ged Y; Horgan AM
J Geriatr Oncol; 2016 Mar; 7(2):57-63. PubMed ID: 26907565
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer.
Arnold P; Penaloza-Ramos MC; Adedokun L; Rees S; Lockhat M; Spary L; Watkins A; Gnanapragasam V; Crabb SJ
Sci Rep; 2021 Nov; 11(1):22151. PubMed ID: 34772971
[TBL] [Abstract][Full Text] [Related]
17. Management of non-metastatic castrate-resistant prostate cancer: A systematic review.
Loriot Y; Supiot S; Beauval JB; Schlürmann F; Pasticier G; Sargos P; Barthélémy P; Pignot G; Maillet D; Vincendeau S; Gross E; Ploussard G; Timsit MO; Borchiellini D
Cancer Treat Rev; 2018 Nov; 70():223-231. PubMed ID: 30300771
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis.
Hird AE; Dvorani E; Saskin R; Emmenegger U; Herschorn S; Kodama R; Kulkarni GS; Nam RK
Clin Genitourin Cancer; 2023 Apr; 21(2):e27-e34. PubMed ID: 36371403
[TBL] [Abstract][Full Text] [Related]
19. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
Virgo KS; Basch E; Loblaw DA; Oliver TK; Rumble RB; Carducci MA; Nordquist L; Taplin ME; Winquist E; Singer EA
J Clin Oncol; 2017 Jun; 35(17):1952-1964. PubMed ID: 28441112
[TBL] [Abstract][Full Text] [Related]
20. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives.
Berruti A; Bracarda S; Caffo O; Cortesi E; D'Angelillo R; Del Re M; Facchini G; Pappagallo G; Procopio G; Sabbatini R; Santini D
Cancer Treat Rev; 2023 Apr; 115():102525. PubMed ID: 36822009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
